 Clinical Trials as Topic
"Clinical Trials as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
| Descriptor ID |
D002986
|
| MeSH Number(s) |
E05.318.760.250.500 N05.715.360.775.088.500 N06.850.520.450.250.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials as Topic".
This graph shows the total number of publications written about "Clinical Trials as Topic" by people in this website by year, and whether "Clinical Trials as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 2 | 3 | | 1993 | 1 | 4 | 5 | | 1994 | 0 | 7 | 7 | | 1995 | 2 | 7 | 9 | | 1996 | 2 | 7 | 9 | | 1997 | 1 | 13 | 14 | | 1998 | 4 | 9 | 13 | | 1999 | 2 | 11 | 13 | | 2000 | 0 | 12 | 12 | | 2001 | 1 | 18 | 19 | | 2002 | 5 | 22 | 27 | | 2003 | 2 | 19 | 21 | | 2004 | 4 | 26 | 30 | | 2005 | 4 | 32 | 36 | | 2006 | 4 | 22 | 26 | | 2007 | 7 | 21 | 28 | | 2008 | 8 | 21 | 29 | | 2009 | 10 | 28 | 38 | | 2010 | 6 | 33 | 39 | | 2011 | 11 | 27 | 38 | | 2012 | 15 | 27 | 42 | | 2013 | 7 | 23 | 30 | | 2014 | 6 | 25 | 31 | | 2015 | 8 | 28 | 36 | | 2016 | 10 | 29 | 39 | | 2017 | 13 | 25 | 38 | | 2018 | 17 | 23 | 40 | | 2019 | 7 | 26 | 33 | | 2020 | 11 | 12 | 23 | | 2021 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials as Topic" by people in Profiles.
-
Wallimann T, Hall CHT, Colgan SP, Glover LE. Creatine Supplementation for Patients with Inflammatory Bowl Diseases: A Scientific Rationale for a Clinical Trial. Nutrients. 2021 Apr 23; 13(5).
-
Lexchin J, Bero LA, Davis C, Gagnon MA. Achieving greater independence from commercial influence in research. BMJ. 2021 03 09; 372:n370.
-
Tong A, Baumgart A, Evangelidis N, Viecelli AK, Carter SA, Azevedo LC, Cooper T, Bersten A, Cervantes L, Chew DP, Crowe S, Douglas IS, Flemyng E, Elliott JH, Hannan E, Horby P, Howell M, Ju A, Lee J, Lorca E, Lynch D, Manera KE, Marshall JC, Gonzalez AM, McKenzie A, Mehta S, Mer M, Morris AC, Needham DM, Nseir S, Povoa P, Reid M, Sakr Y, Shen N, Smyth AR, Simpson AJ, Snelling T, Strippoli GFM, Teixeira-Pinto A, Torres A, Turner T, Webb S, Williamson PR, Woc-Colburn L, Zhang J, Craig JC. Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. Crit Care Med. 2021 03 01; 49(3):503-516.
-
Griffin DO, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L, Iglesias J, Dube M, Nanda N, In GK, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer D, Ehresmann G, Peng D, Smorgorzewski M, Amstrong A, Vinjevoll EH, Dasgupta R, Sattler FR, Mussini C, Mitjà O, Soriano V, Peschanski N, Hayem G, Piccirillo MC, Lobo-Ferreira A, Rivero IB, Hung IFH, Rendell M, Ditmore S, Varon J, Marik P. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Rev. 2021 02 08; 23(1):40-47.
-
Shallis RM, Pollyea DA, Zeidan AM. Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials. Lancet Haematol. 2020 12; 7(12):853-856.
-
Berg AT, Palac H, Wilkening G, Zelko F, Schust Meyer L. SCN2A-Developmental and Epileptic Encephalopathies: Challenges to trial-readiness for non-seizure outcomes. Epilepsia. 2021 01; 62(1):258-268.
-
Abraham WT, Psotka MA, Fiuzat M, Filippatos G, Lindenfeld J, Mehran R, Ambardekar AV, Carson PE, Jacob R, Januzzi JL, Konstam MA, Krucoff MW, Lewis EF, Piccini JP, Solomon SD, Stockbridge N, Teerlink JR, Unger EF, Zeitler EP, Anker SD, O'Connor CM. Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. Eur J Heart Fail. 2020 12; 22(12):2175-2186.
-
Chastain DB, Henao-Martínez AF, Young HN. Racial Disproportionality in Covid Clinical Trials. Reply. N Engl J Med. 2020 12 17; 383(25):2488-2490.
-
Li X, Sigworth EA, Wu AH, Behrens J, Etemad SA, Nagpal S, Go RS, Wuichet K, Chen EJ, Rubinstein SM, Venepalli NK, Tillman BF, Cowan AJ, Schoen MW, Malty A, Greer JP, Fernandes HD, Seifter A, Chen Q, Chowdhery RA, Mohan SR, Dewdney SB, Osterman T, Ambinder EP, Buchbinder EI, Schwartz C, Abraham I, Rioth MJ, Singh N, Sharma S, Gibson MK, Yang PC, Warner JL. Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis. Sci Rep. 2020 10 16; 10(1):17536.
-
Slavova S, LaRochelle MR, Root ED, Feaster DJ, Villani J, Knott CE, Talbert J, Mack A, Crane D, Bernson D, Booth A, Walsh SL. Operationalizing and selecting outcome measures for the HEALing Communities Study. Drug Alcohol Depend. 2020 12 01; 217:108328.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|